Navitoclax Combined with Daunorubicin Promotes Apoptosis of Erythroleukemia Cell Lines K562, HEL and TF-1.
10.19746/j.cnki.issn.1009-2137.2020.03.002
- Author:
Yong-Juan DUAN
1
;
Chao LIU
1
;
Xiao-Yan CHEN
1
;
Wen-Qi WU
1
;
Jia-Rui ZHENG
2
;
Ying-Chi ZHANG
3
;
Xiao-Fan ZHU
4
Author Information
1. Pediatric Leukemia Diagnosis and Treatment Center, Institute of Hematology and Blood Disease Hospital of Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300020, China.
2. Tianjin Medical University, Tianjin 300070, China.
3. Pediatric Leukemia Diagnosis and Treatment Center, Institute of Hematology and Blood Disease Hospital of Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300020, China,E-mail: zhangyingchi@ihcams.ac.cn.
4. Pediatric Leukemia Diagnosis and Treatment Center, Institute of Hematology and Blood Disease Hospital of Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300020, China,E-mail: xfzhu@ihcams.ac.cn.
- Publication Type:Journal Article
- MeSH:
Aniline Compounds;
Apoptosis;
Daunorubicin;
Humans;
K562 Cells;
Leukemia, Erythroblastic, Acute;
Sulfonamides
- From:
Journal of Experimental Hematology
2020;28(3):724-730
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To study the effect of apoptotic drug Navitoclax (NTX) combined with chemotherapy drug Daunorubicin (DNR) on apoptosis of erythroleukemia cells.
METHODS:K562, HEL and TF-1 cells in logarithmic growth phase were treated with NTX, DNR and combination of the two drugs. CCK-8 test, Annexin V-DAPI double-staining flow cytometry, real-time RT-PCR were used to detect cell growth, cell apoptosis and expression of BAX, BAK, BCL-2, BCL-xl and BIM respectively. The effects of NTX, DNR and combination of the two drugs on apoptosis of K562, HEL and TF-1 cells were compared and analyzed.
RESULTS:NTX combined with DNR could significantly inhibit the growth of K562, HEL and TF-1 cells; Apoptosis detection results showed that the apoptotic rate of K562, HEL and TF-1 cells in combination group was significantly higher than that in NTX and DNR single group; the expression level of apoptosis-related genes BAK and BAX in K562 cells in combination group was significantly higher than that in two single drug groups, and the expression level of anti-apoptotic protein genes BCL-2 and BCL-xl was significantly lower than that in two single drug groups (P＜0.05); the expression level of BAK in HEL cells treated with combined drugs for 24 hours was higher than that in DNR group (P ＜ 0.05); the expression level of BCL-2 in TF-1 cells treated with combined drugs for 24 hours was lower than that in two single drugs groups while the expression level of BAK in 48 hours was the highest in combined drugs group, and the expression level of BCL-2 and BCL-xl in combined drugs group was lower than that in NTX group (P＜0.05).
CONCLUSION:NTX combined with DNR can significantly promote the apoptosis of erythroleukemia cell lines K562, HEL and TF-1, and induce the expression of apoptosis-related genes. This study provides a new scheme for the clinical treatment of erythroleukemia.
